Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration

About This Study

The study design matches with a multicenter observational ambispective study. A first pilot study will be undertaken in Caen center and is expected to be extended to Rouen and Lille center. So patients from Normandy and North-West areas will be included. In order to include patients in this observational study historical data about first line injectable treatments (interferons and glatiramer acetate) are used. As well as the data on patients treated with oral first line therapies (teriflunomide and dimethyl fumarate) began to be collected ahead of the study start (Retrospective phase). During the course of the study, new patients under teriflunomide or dimethyl fumarate will be included (Prospective phase).

Conditions Studied

Interventions

• •Delay between MS onset and introduction of first line DMT
• •EDI

Eligibility

Inclusion Criteria:

* Patients registered in EDMUS database.
* Patients with an initial and definite diagnosis of Relapsing-Remitting Multiple Sclerosis.
* An established diagnosis from January 1st 1995 to the end of the study.

Exclusion Criteria:

* Patients not registered in EDMUS database.
* Patient with a diagnosis of Primary Progressive Multiple Sclerosis
* Patients with a diagnosis established before January 1st 1995

Study Locations (4)